Improving Life through
Pacific GeneTech develops and commercializes next-generation vaccines and biological targeting areas of high unmet need. Our vaccines, initially created for veterinary applications, use "Aegis", a proprietary technology platform enabling broad-spectrum protection across related pathogens. They can be administered orally or by injection in both live and inactivated forms. All our inactivated vaccines incorporate our "Hercules" adjuvant / delivery system.
Pacific GeneTech is led by an experienced management team supported by top scientific and industry advisors expert in R&D, business development and in the process of commercializing products for the market. The Company's management expertise encompasses both veterinary and human medicine.
We target the intestinal bacteria Salmonella, E. coli, Campylobacter and Shigella; parasites such as Eimeria, Toxoplasma, Cryptosporidium and Plasmodium (malaria); and viruses such as Influenza A. Poultry vaccines for Salmonella and Eimeria are in the USDA’s regulatory process and submissions for Salmonella in pigs and Toxoplasma and Cryptosporidium in ruminants are planned. Collaborations for human dysentery and malaria are in place.